Group 1 - Monteverde & Associates PC is investigating Alimera Sciences, Inc. regarding its proposed merger with ANI Pharmaceuticals, Inc. [1] - Under the merger agreement, Alimera Sciences shareholders will receive $5.50 per share, along with a contingent value right that could yield up to $0.50 per share based on specific net revenue targets in 2026 and 2027 [1] - Monteverde & Associates PC has been recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report, highlighting its successful track record in recovering money for shareholders [1][2] Group 2 - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] - Monteverde & Associates PC emphasizes that no company, director, or officer is above the law, indicating a commitment to shareholder rights [2] - The firm encourages shareholders with concerns to reach out for additional information at no cost [2]
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM